Phase 4
N=23
Effects of Oral Zinc Gluconate Among Acne Vulgaris Patients
Acne Vulgaris
Bottom Line
View on ClinicalTrials.gov: NCT05096312 ↗Enrolled (actual)
23
Serious AEs
0.0%
Results posted
Apr 2022
Primary outcome: Primary: Global Acne Grading System Score — 32; 30.33; 21.67; 27.5 score on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Zinc gluconate (Dietary_supplement); Adapalene 0.003 MG/MG / Benzoyl Peroxide 0.025 MG/MG Topical Gel [Epiduo] (Drug); Placebo (Other)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- East Avenue Medical Center, Philippines
- Primary completion
- Jul 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Global Acne Grading System Score |
32; 30.33; 21.67; 27.5; 14.34; 21.67 | — |
| PRIMARY Inflammatory Score |
70; 48.5; 22.67; 47.5; 8.34; 22.67 | — |
| SECONDARY Examiner's Assessment Score |
0; 0; 0; 0; 8; 8 | — |
| SECONDARY Patient's Self-assessment Score |
0; 0; 0; 0; 8; 8 | — |
Summary
Acne Vulgaris is one of the most common dermatologic diagnoses requiring long-term maintenance therapy. Promising results of oral zinc gluconate in improving acne vulgaris has been described.
A randomized, double blind, placebo-controlled clinical trial was utilized for this study with the objective to assess the efficacy of oral zinc gluconate in the improvement of disease activity in acne vulgaris patients as measured by the inflammatory score and Global Acne Grading System (GAGS) score.
Eligibility Criteria
Inclusion Criteria
- Filipino patients, aged 18-27 years old
- New patients diagnosed with Acne Vulgaris with a Global Acne Grading System score of at least 19
- Able to read and write in English or Tagalog
- Seen at the Dermatology out-patient clinic of East Avenue Medical Center
Exclusion Criteria
- Patients with other chronic dermatoses or systemic disease
- Taking oral supplements or medications within the past 4 weeks
- Patients who are pregnant or lactating
Data sourced from ClinicalTrials.gov (NCT05096312). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.